Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors
0 بازدیدها
administrator
07/09/23
From ASCO 2011 -- A discussion with Prof. Eric Raymond on his poster presented at ASCO in June 2011 titled "Updated Overall Survival (OS) and Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) of Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors (NET)"
بیشتر نشان بده، اطلاعات بیشتر
نظرات فیس بوک
نظری یافت نشد